Zydus Lifesciences will consider raising up to ₹5,000 crore via multiple routes, including QIP and rights issue, as it prepares to announce its Q2 results.
Read Full
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
